JP2013529070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529070A5 JP2013529070A5 JP2013505070A JP2013505070A JP2013529070A5 JP 2013529070 A5 JP2013529070 A5 JP 2013529070A5 JP 2013505070 A JP2013505070 A JP 2013505070A JP 2013505070 A JP2013505070 A JP 2013505070A JP 2013529070 A5 JP2013529070 A5 JP 2013529070A5
- Authority
- JP
- Japan
- Prior art keywords
- scaffold
- seq
- multimeric
- multimeric scaffold
- monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000178 monomer Substances 0.000 claims 10
- 102000004965 antibodies Human genes 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 102000007193 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 4
- 108010008478 TNF-Related Apoptosis-Inducing Ligand Proteins 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 102100001249 ALB Human genes 0.000 claims 1
- 101710027066 ALB Proteins 0.000 claims 1
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102100014838 FCGRT Human genes 0.000 claims 1
- 101710003435 FCGRT Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006822 Human Serum Albumin Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 230000002730 additional Effects 0.000 claims 1
- 229940050528 albumin Drugs 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229920000592 inorganic polymer Polymers 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 229920000620 organic polymer Polymers 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002285 radioactive Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108020003112 toxins Proteins 0.000 claims 1
Claims (23)
- 2つのTn3単量体足場を含むTRAIL R2特異的組換え型多量体足場であって、
(a)各Tn3単量体足場が、A、B、C、D、E、F、およびGと命名される7つのベータ鎖、およびAB、BC、CD、DE、EF、およびFGと命名される6つのループ領域を含み、
(b)Tn3単量体足場がタンデムに連結され、さらに
(c)組換え型多量体足場が特異的にTRAIL R2に結合する、
多量体足場。 - 多量体足場が、3、4、5、6、7、または8つのTn3単量体足場を含む、請求項1に記載の多量体足場。
- 全てのTn3単量体足場が、直鎖状タンデムフォーマットになっている、請求項2に記載の多量体足場。
- 少なくとも1つのTn3単量体足場が、直接に、リンカーにより、または異種の成分により、1、2、3、4、5、6、または7つの他のTn3単量体足場に連結されている、請求項1〜3のいずれか1項に記載の多量体足場。
- 少なくとも2つのTn3単量体足場が、ペプチドリンカーを含むリンカーにより連結されている、請求項4に記載の多量体足場。
- ペプチドリンカーが、(GxS)y配列を含み、ここで:
xおよびyは整数であり;
x=1、2、3または4であり;
y=1、2、3、4、5、6、または7であり;且つ
場合によりx=4およびy=1である、
請求項5に記載の多量体足場。 - 少なくとも1つのTn3単量体足場が、異種の成分に融合されている、請求項1〜6のいずれか1項に記載の多量体足場。
- 異種の成分が、タンパク質、ペプチド、タンパク質ドメイン、リンカー、薬剤、毒素、細胞傷害性薬物、造影剤、放射性核種、放射性化合物、有機ポリマー、無機ポリマー、ポリエチレングリコール(PEG)、ビオチン、ヒト血清アルブミン(HSA)、HSA FcRn結合部分、抗体、抗体のドメイン、抗体断片、単鎖抗体、ドメイン抗体、アルブミン結合ドメイン、酵素、リガンド、受容体、結合ペプチド、非FnIII足場、エピトープタグ、組換え型ポリペプチドポリマー、サイトカイン、および前記成分の2つ以上の組み合わせ、からなる群より選択される組成物を含む、請求項7に記載の多量体足場。
- 足場がPEGにコンジュゲートされており、場合により足場がN末端またはC末端でPEGにコンジュゲートされている、請求項8に記載の多量体足場。
- 多量体足場が受容体アゴニストである、請求項1〜9のいずれか1項に記載の多量体足場。
- 少なくとも2つのTn3単量体足場がTRAIL R2上の同じエピトープに結合する、請求項1〜10のいずれか1項に記載の多量体足場。
- 少なくとも2つのTn3単量体足場がTRAIL R2上の異なるエピトープに結合する、請求項1〜11のいずれか1項に記載の多量体足場。
- 少なくとも2つのTn3単量体足場がアミノ酸配列:
IEV(XAB)nALITW(XBC)nCELX1YGI(XCD)nTTIX2L(XDE)nYSI(XEF)nYEVSLIC(XFG)nKX3TFTT
を含み、ここで:
XAB、XBC、XCD、XDE、XEF、およびXFGは、AB、BC、CD、DE、EF、およびFGループ中に存在するアミノ酸残基をそれぞれ表し;
X1はアミノ酸残基AまたはTを表し;
X2はアミノ酸残基DまたはGを表し;
X3はアミノ酸EまたはGを表し;
さらにループの長さnは2〜26の整数であり;且つ
場合により;
ABループが配列番号35を含み、CDループが配列番号37を含み、さらにEFループは配列番号39を含み;および/または
BCループが、配列番号97、98、または168からなる群より選択される配列を含み;および/または
DEループが、配列番号102、103、および179からなる群より選択される配列を含み;および/または
FGループが、配列番号106、108、109、169、および170からなる群より選択される配列を含み;および/または
BCループが配列番号97を含み、DEループが配列番号179を含み、さらにFGループが配列番号170を含む、請求項1〜12のいずれか1項に記載の多量体足場。 - 足場が配列番号202、配列番号203、配列番号204、または配列番号167を含む、請求項1〜13のいずれか1項に記載の多量体足場。
- 請求項1〜14のいずれか1項の多量体足場をコードする単離核酸分子。
- 請求項15に記載の核酸を含む発現ベクター。
- 請求項16に記載のベクターを含む宿主細胞。
- 核酸分子によりコードされた多量体足場が発現する条件下、請求項17に記載の宿主細胞を培養するステップを含む組換え型多量体足場の製造方法。
- 薬学的に許容可能な賦形剤中に請求項1〜14のいずれか1項に記載の組換え型多量体足場を含む組成物。
- 有効量の請求項19に記載の組成物を投与することにより、癌の予防、治療、改善、または管理を、それを必要とする患者において行う方法。
- TRAIL R2を発現している細胞のアポトーシスを誘導する方法であって、該細胞を請求項1〜14のいずれか1項に記載の組換え型多量体足場と接触させることを含む、方法。
- 前記癌が、肺癌、非ホジキンリンパ腫、卵巣癌、結腸癌、結腸直腸癌、膵臓癌、および多発性骨髄腫、から選択される、請求項20に記載の方法。
- 前記方法が、追加の療法をさらに含み、その療法が免疫療法、生物学的療法、化学療法、放射線療法、または小分子薬物療法である、請求項20〜22のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32370810P | 2010-04-13 | 2010-04-13 | |
US61/323,708 | 2010-04-13 | ||
PCT/US2011/032188 WO2011130328A1 (en) | 2010-04-13 | 2011-04-12 | Trail r2-specific multimeric scaffolds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013529070A JP2013529070A (ja) | 2013-07-18 |
JP2013529070A5 true JP2013529070A5 (ja) | 2014-04-10 |
JP6041799B2 JP6041799B2 (ja) | 2016-12-14 |
Family
ID=44799000
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013505069A Pending JP2013523179A (ja) | 2010-04-13 | 2011-04-12 | フィブロネクチンタイプiiiドメインに基づく多量体足場 |
JP2013505070A Active JP6041799B2 (ja) | 2010-04-13 | 2011-04-12 | Trailr2特異的多量体足場 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013505069A Pending JP2013523179A (ja) | 2010-04-13 | 2011-04-12 | フィブロネクチンタイプiiiドメインに基づく多量体足場 |
Country Status (13)
Country | Link |
---|---|
US (2) | US9212231B2 (ja) |
EP (2) | EP2558495B1 (ja) |
JP (2) | JP2013523179A (ja) |
KR (2) | KR20130056870A (ja) |
CN (2) | CN102834114A (ja) |
AU (2) | AU2011240624B2 (ja) |
BR (1) | BR112012026003B1 (ja) |
CA (2) | CA2795325A1 (ja) |
ES (1) | ES2755398T3 (ja) |
MX (1) | MX341119B (ja) |
RU (1) | RU2628699C2 (ja) |
SG (2) | SG10201505470QA (ja) |
WO (2) | WO2011130328A1 (ja) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
MX2010008874A (es) | 2008-02-14 | 2010-09-22 | Bristol Myers Squibb Co | Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico. |
CN102099373A (zh) | 2008-05-22 | 2011-06-15 | 百时美施贵宝公司 | 基于纤连蛋白的多价支架结构域蛋白 |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
CA2795325A1 (en) * | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
DK2697257T3 (en) | 2011-04-13 | 2017-01-30 | Bristol Myers Squibb Co | FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS |
US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
US9347058B2 (en) | 2011-05-17 | 2016-05-24 | Bristol-Myers Squibb Company | Methods for the selection of binding proteins |
DK2771022T3 (da) * | 2011-10-11 | 2020-09-28 | Viela Bio Inc | Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf |
EP2773659A2 (en) | 2011-10-31 | 2014-09-10 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
HUE038668T2 (hu) | 2011-11-08 | 2018-11-28 | Umc Utrecht Holding Bv | Interleukin-4-et és interleukin-10-et tartalmazó fúziós fehérje |
PE20150954A1 (es) | 2012-09-13 | 2015-06-20 | Bristol Myers Squibb Co | Proteinas del dominio de soporte basadas en fibronectina que se fijan a miostatina |
US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
WO2014120891A2 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
ES2689372T3 (es) | 2013-02-06 | 2018-11-13 | Bristol-Myers Squibb Company | Proteínas de dominio de fibronectina tipo III con solubilidad mejorada |
WO2014126871A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
ES2645634T3 (es) | 2013-02-12 | 2017-12-07 | Bristol-Myers Squibb Company | Métodos de replegado de proteínas a elevado pH |
EP2968587A2 (en) | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
WO2014159562A1 (en) | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
US10392611B2 (en) | 2013-05-30 | 2019-08-27 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
US10364451B2 (en) | 2013-05-30 | 2019-07-30 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
CN105899226B (zh) | 2013-10-14 | 2020-05-12 | 詹森生物科技公司 | 半胱氨酸工程化iii型纤连蛋白域结合分子 |
WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
CN113150117A (zh) | 2014-03-20 | 2021-07-23 | 百时美施贵宝公司 | 新的结合血清白蛋白的纤连蛋白iii型结构域 |
MX371403B (es) | 2014-03-20 | 2020-01-29 | Bristol Myers Squibb Co | Moleculas de andamiaje a base de fibronectina estabilizada. |
WO2015148269A2 (en) * | 2014-03-24 | 2015-10-01 | Medimmune, Llc | Stabilized tnfn3 scaffold proteins |
NO2776305T3 (ja) | 2014-04-23 | 2018-01-27 | ||
CN106573961B (zh) * | 2014-06-20 | 2022-01-04 | 豪夫迈·罗氏有限公司 | 基于chagasin的支架组合物、方法和应用 |
BR112017006602A2 (pt) | 2014-10-01 | 2017-12-19 | Medimmune Llc | método de conjugação de um polipeptídeo |
JP6701217B2 (ja) | 2014-11-25 | 2020-05-27 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 生物学的製剤の18f−放射性標識方法および組成物 |
ES2839211T3 (es) | 2015-03-12 | 2021-07-05 | Medimmune Llc | Método para purificar proteínas de fusión a albúmina |
WO2016154530A1 (en) * | 2015-03-26 | 2016-09-29 | Duke University | Targeted therapeutic agents comprising multivalent protein-biopolymer fusions |
JP7019423B2 (ja) * | 2015-05-06 | 2022-02-15 | ヤンセン バイオテツク,インコーポレーテツド | 前立腺特異的膜抗原(psma)二重特異性結合剤及びその使用 |
CA2994279A1 (en) | 2015-08-04 | 2017-02-09 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
US11124791B2 (en) | 2015-09-14 | 2021-09-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Generating recombinant affinity reagents with arrayed targets |
US10766946B2 (en) | 2015-09-23 | 2020-09-08 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type III domains |
CN108884147B (zh) * | 2015-09-23 | 2024-02-27 | 百时美施贵宝公司 | 结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子 |
KR20180100302A (ko) * | 2015-10-23 | 2018-09-10 | 우니베르지태트 트벤테 | 인테그린 결합 펩티드 및 그의 용도 |
CN108601819B (zh) | 2015-12-17 | 2022-03-15 | 约翰霍普金斯大学 | 用死亡受体激动剂改善系统性硬化症 |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
JP7281795B2 (ja) | 2016-04-07 | 2023-05-26 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 |
CN105802970A (zh) * | 2016-05-30 | 2016-07-27 | 东北师范大学 | 靶向沉默Gβ1的shRNA |
US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
AU2017281083B2 (en) | 2016-06-21 | 2022-01-27 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
WO2018053201A1 (en) | 2016-09-14 | 2018-03-22 | Duke University | Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs |
KR20190064600A (ko) | 2016-09-23 | 2019-06-10 | 듀크 유니버시티 | Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드 |
US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
JP7104703B2 (ja) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク,インコーポレーテツド | Cd8a結合フィブロネクチンiii型ドメイン |
EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
US10787499B2 (en) * | 2017-02-13 | 2020-09-29 | Regents Of The University Of Minnesota | EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof |
US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS |
US11491206B1 (en) | 2018-02-13 | 2022-11-08 | Duke University | Compositions and methods for the treatment of trail-resistant cancer |
US11680091B2 (en) | 2018-02-23 | 2023-06-20 | The University Of Chicago | Methods and composition involving thermophilic fibronectin type III (FN3) monobodies |
EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
CN110724198B (zh) * | 2018-07-17 | 2023-05-26 | 上海一宸医药科技有限公司 | 长效纤连蛋白iii型结构域融合蛋白 |
WO2020028806A1 (en) | 2018-08-02 | 2020-02-06 | Duke University | Dual agonist fusion proteins |
EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
EP3715376A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
WO2020212602A1 (en) | 2019-04-19 | 2020-10-22 | Synerkine Pharma B.V. | Therapeutic crosslinking of cytokine receptors |
UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
US20220396631A1 (en) | 2019-05-21 | 2022-12-15 | Lu HUANG | Trispecific binding molecules against bcma and uses thereof |
WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
EP3999091A1 (en) | 2019-07-15 | 2022-05-25 | MedImmune Limited | Tripartite systems for protein dimerization and methods of use |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
WO2021076546A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
CN111217903B (zh) * | 2020-02-25 | 2022-11-15 | 芜湖天明生物技术有限公司 | 一种重组人纤连蛋白ⅲ1-c及其制备方法和应用 |
WO2021174045A1 (en) | 2020-02-28 | 2021-09-02 | Bristol-Myers Squibb Company | Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof |
JP2023520773A (ja) | 2020-03-27 | 2023-05-19 | ノバルティス アーゲー | 増殖性疾患及び自己免疫疾患を治療するための二重特異性組合せ治療 |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
CN111944204B (zh) * | 2020-07-24 | 2022-03-08 | 南京理工大学 | 一种Fe3O4磁性细菌纤维素及其制备方法 |
TW202228784A (zh) | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗peg抗體的化合物 |
IL301332A (en) | 2020-09-23 | 2023-05-01 | Ablevia Biotech Gmbh | A compound for preventing or treating conditions mediated by autoantibodies |
US20230365655A1 (en) | 2020-09-23 | 2023-11-16 | Ablevia Biotech Gmbh | Compound for increasing the efficacy of factor viii replacement therapy |
US20230381334A1 (en) | 2020-09-23 | 2023-11-30 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
US20230355747A1 (en) | 2020-09-23 | 2023-11-09 | Ablevia Biotech Gmbh | Compound for increasing efficacy of viral vectors |
CN116710143A (zh) | 2020-09-24 | 2023-09-05 | 艾柏力维亚生技有限公司 | 用于预防或治疗重症肌无力的化合物 |
CA3199095A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
MX2023005234A (es) | 2020-11-06 | 2023-05-18 | Novartis Ag | Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b. |
CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
WO2023180502A1 (en) | 2022-03-24 | 2023-09-28 | Ablevia Biotech Gmbh | Compound for increasing efficacy of oncolytic viruses |
KR102459313B1 (ko) * | 2022-04-11 | 2022-10-26 | 주식회사 대영방재산업 | 내구성이 개선된 소방용 수격 흡수기 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0781297A4 (en) | 1994-09-16 | 1999-05-19 | Scripps Research Inst | CYTOTACTINE DERIVATIVES THAT STIMULATE NEURONAL CONNECTION AND GROWTH OF AXONES AND DENDRITES, THEIR PREPARATION AND USE METHODS |
CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
AU731758B2 (en) | 1998-07-08 | 2001-04-05 | Mitsui Chemicals, Inc. | Method for secretory production of human growth hormone |
AU766551C (en) * | 1998-08-28 | 2005-02-17 | Genentech Inc. | Human anti-factor IX/IXa antibodies |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
EP2154535A1 (en) | 1998-12-10 | 2010-02-17 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
EP2339017A3 (en) | 2002-03-29 | 2011-10-12 | Genencor International, Inc. | Enhanced protein expression in bacillus |
AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
WO2004001009A2 (en) | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
EP1710255A4 (en) * | 2003-12-12 | 2008-09-24 | Chugai Pharmaceutical Co Ltd | MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR |
GB0416651D0 (en) | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
CN101300273B (zh) * | 2005-08-31 | 2013-05-22 | 安姆根有限公司 | Trail受体2多肽和抗体 |
US10183986B2 (en) * | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
BRPI0621413A2 (pt) | 2006-02-13 | 2011-12-06 | Agency Science Tech & Res | método de processamento de uma amostra biológica e/ou quìmica |
CN101074261A (zh) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
WO2009023184A2 (en) | 2007-08-10 | 2009-02-19 | Protelix, Inc. | Universal fibronectin type iii binding-domain libraries |
US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
WO2009058379A2 (en) * | 2007-10-31 | 2009-05-07 | Medimmune, Llc | Protein scaffolds |
KR20100111283A (ko) | 2007-12-27 | 2010-10-14 | 노파르티스 아게 | 개선된 피브로넥틴계 결합 분자 및 그들의 용도 |
EP2274331B1 (en) | 2008-05-02 | 2013-11-06 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
CN102099373A (zh) * | 2008-05-22 | 2011-06-15 | 百时美施贵宝公司 | 基于纤连蛋白的多价支架结构域蛋白 |
CA2739663A1 (en) * | 2008-10-10 | 2010-05-15 | Anaphore, Inc. | Polypeptides that bind trail-r1 and trail-r2 |
DK2356269T3 (en) | 2008-10-31 | 2016-08-15 | Janssen Biotech Inc | FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
EP2464663A4 (en) | 2009-08-13 | 2013-05-29 | Massachusetts Inst Technology | RECOMBINANT PROTEINS COMPRISING MUTANT DOMAINS OF FIBRONECTIN |
CA2795325A1 (en) * | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
-
2011
- 2011-04-12 CA CA2795325A patent/CA2795325A1/en not_active Abandoned
- 2011-04-12 AU AU2011240624A patent/AU2011240624B2/en active Active
- 2011-04-12 EP EP11769481.0A patent/EP2558495B1/en active Active
- 2011-04-12 WO PCT/US2011/032188 patent/WO2011130328A1/en active Application Filing
- 2011-04-12 BR BR112012026003-0A patent/BR112012026003B1/pt active IP Right Grant
- 2011-04-12 SG SG10201505470QA patent/SG10201505470QA/en unknown
- 2011-04-12 US US13/639,381 patent/US9212231B2/en active Active
- 2011-04-12 SG SG2012070108A patent/SG184185A1/en unknown
- 2011-04-12 JP JP2013505069A patent/JP2013523179A/ja active Pending
- 2011-04-12 AU AU2011240620A patent/AU2011240620A1/en not_active Abandoned
- 2011-04-12 RU RU2012147960A patent/RU2628699C2/ru active
- 2011-04-12 CN CN2011800187879A patent/CN102834114A/zh active Pending
- 2011-04-12 CN CN201180018796.8A patent/CN102906112B/zh active Active
- 2011-04-12 MX MX2012011840A patent/MX341119B/es active IP Right Grant
- 2011-04-12 EP EP11769477.8A patent/EP2560684A4/en not_active Withdrawn
- 2011-04-12 KR KR1020127029343A patent/KR20130056870A/ko not_active Application Discontinuation
- 2011-04-12 US US13/640,057 patent/US20130079280A1/en not_active Abandoned
- 2011-04-12 KR KR1020127029323A patent/KR101747991B1/ko active IP Right Grant
- 2011-04-12 JP JP2013505070A patent/JP6041799B2/ja active Active
- 2011-04-12 WO PCT/US2011/032184 patent/WO2011130324A1/en active Application Filing
- 2011-04-12 ES ES11769481T patent/ES2755398T3/es active Active
- 2011-04-12 CA CA2796010A patent/CA2796010C/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013529070A5 (ja) | ||
RU2012147960A (ru) | Trail r2-специфические мультимерные скаффолды | |
US10214579B2 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
Lipovšek | Adnectins: engineered target-binding protein therapeutics | |
Stork et al. | A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G | |
CN105658235B (zh) | 能够结合gpA33和CD3的双特异性单价双抗体及其用途 | |
EP1888641B1 (en) | Serum albumin binding proteins | |
JP2018512145A5 (ja) | ||
JP6618463B2 (ja) | 三量体型抗原結合分子 | |
US11987619B2 (en) | Single-chain chimeric polypeptides and uses thereof | |
RU2017134140A (ru) | Конструкции, направленные на комплексы пептида аfp/мнс, и виды их использования | |
JP2021502810A5 (ja) | ||
JP2019522490A5 (ja) | ||
JP2017529067A5 (ja) | ||
JP2011501951A5 (ja) | ||
CN103965363B (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
CA2561826A1 (en) | Linear single chain recombinant anti-cea/cd3/cd28 trispecific antibody | |
JP2012531212A5 (ja) | ||
CA3001264A1 (en) | Pd-l1 binding polypeptide | |
CN111699000A (zh) | 靶沉默技术的细胞内递送 | |
JP2020519293A5 (ja) | ||
EP4130046A1 (en) | Platform for constructing multispecific antibody | |
JP2015520172A5 (ja) | ||
JP2008507253A5 (ja) | ||
CA3117853A1 (en) | Novel rationally designed protein compositions |